(Q38178105)

30 August 2017

title

Neuro-oncology in 2013: improving outcome in newly diagnosed malignant glioma (English)

1 reference

30 August 2017

1

Michael Weller

1 reference

30 August 2017

2

Wolfgang Wick

1 reference

30 August 2017

language of work or name

English

0 references

publication date

14 January 2014

1 reference

30 August 2017

published in

Nature Reviews Neurology

1 reference

30 August 2017

volume

10

1 reference

30 August 2017

issue

2

1 reference

30 August 2017

page(s)

68-70

1 reference

https://scigraph.springernature.com/pub.10.1038/nrneurol.2013.268

30 August 2017

exact match

0 references

cites work

Molecular neuro-oncology in clinical practice: a new horizon

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.268

Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.268

The somatic genomic landscape of glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.268

Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.268

Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.268

NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.268

Prognostic or predictive value of MGMT promoter methylation in gliomas depends on IDH1 mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.268

Neurocognitive function in patients with recurrent glioblastoma treated with bevacizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.268

Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24419684

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1038/NRNEUROL.2013.268

1 reference

Dimensions Publication ID

30 August 2017

1022780102

0 references

1 reference